Search 

Rockland Technimed Limited is a diagnostic imaging company, committed to the early diagnosis and treatment of ischemic injury, through its patented Oxy-17® metabolic magnetic resonance imaging medium.

Rockland Technimed Limited (RTL) is a theranostic imaging company committed to the early diagnosis and treatment of hypoxic injury through Oxy-17®, its patented metabolic magnetic resonance imaging medium.  RTL has the world’s largest production source of Oxy-17® Gas, an enriched form of naturally available oxygen, in compliance with the cGMP requirement for medical gases, and commercially available in the United States and European Union for more than 20 years.  RTL’s lead preclinical candidate, Oxy-17® Fusion, is the first ready-to-use intravenous formulation of Oxy-17® Gas and is currently in regulatory marketing studies in Germany (European Union) and the United States.  Oxy-17® Fusion will be commercialized in the United States by RTL, and in the European Union with Nukem Isotopes GmbH. 

International Epidemiologist with wide ranging expertise in chronic and infectious diseases & interdisciplinary collaborations.

Private email:  stanweiss @ verizon.net

Stanley H. Weiss, MD has been on the RBHS (and legacy UMDNJ) faculties since 1987, and currently is Professor (with tenure) of Medicine at the New Jersey Medical School, and Professor of Epidemiology at the Rutgers School of Public Health. 

He graduated from Yale (1974, BA, summa cum laude and Phi Beta Kappa) and Harvard Medical School (1978, MD). He did a residency in Internal Medicine at Montefiore in the Bronx, and fellowships at the National Cancer Institute in Medical Oncology and in Epidemiology. Dr. Weiss is Board Certified in Internal Medicine and in Medical Oncology, and a fellow of the American College of Epidemiology (“FACE”) and the American College of Physicians (“FACP”).   

On November 2nd, 2015, he will be honored by the American Public Health Association with its Wade Hampton Frost Lecture, its top epidemiology research  award. 

His past professional awards include the NJ Public Health Association’s (NJPHA) highest award – the Dennis J. Sullivan Award (2012), the NJPHA Dr. Ezra Mundy Hunt Award (2007), the first recipient of the American Lung Association of NJ’s “CAREforAIRnj Award for Community  Outreach/Action/Advocacy, the “Cancer Liaison Physician Outstanding Performance Award” from the Commission on Cancer of the American College of Surgeons (2010), the Prostate Net’s “In the Know” National Award (2007), the UMDNJ School of Public Health “Faculty Community Service Award”(2007), and the first of the American Society of Clinical Oncology “Travel Awards” for outstanding work (1985). At NJMS, he was elected to membership in Sigma Xi chapter (1992) and as a Faculty member to the Alpha Omega Alpha [ΑΩΑ] Honor Medical Society, Beta Chapter (inducted 2003). For the latter, he has served as an officer as the Assistant Secretary/Treasurer since 2006, and helped to develop its Research Award.

Dr. Weiss’ research focuses on epidemiology, public health, study design and methodology, evaluation, policy issues and interdisciplinary studies and projects.  These have primarily been related to cancer, asthma, retroviruses including HIV/AIDS and HTLV, infectious diseases, methodological and policy issues, and bioethics.  In addition, he is the PI of several community-outreach initiatives (including the implementation and evaluation of structured tool sets for individuals to improve their health) and PI/co-PI of a series of studies concerning asthma with key new understanding of asthma epidemiology as well as policy implications.  He is the PI of a set of prospective cohort studies numbering ~10,000 injection drug users begun in the 1980’s, over 30 years ago, which is linked to personal identifying information and  a biospecimen collection of ~ 100,000 vials.  

Dr. Weiss has authored over 350 published, peer-reviewed medical articles, chapters and abstracts. Among his research accomplishments (as lead or senior author, except as noted):

• First assessment of the prototype HIV screening test.
• Part of the team describing the 2nd case worldwide of HTLV-II infection.
• First demonstration of high infection rates with HTLV-II in drug users.
• First report that among persons seropositive for HIV antibody, adverse outcomes had significant latency, and these steadily mounted over time to high rates of severe disease and death.
• First demonstrated US case (2nd worldwide) of occupational acquisition of HIV in healthcare workers, associated this with HIV needlestick) exposure, and leading to vast changes in the workplace.
• First case of occupational acquisition of HV in research workers.
• First US case of HIV-2 – detected at University Hospital, Newark.
• First demonstration of female to male sexual transmission of HIV.
• Part of the team documenting the 2nd case of female to female HIV transmission.
• Wrote substantial parts of the first NJ State Cancer Plan, and then led much of its statewide implementation.
• First demonstration that the latency from initial asbestos exposure until development of mesothelioma is far longer than has been generally understood.
• First to demonstrate that the US epicenter for HIV infection in injection drug users centered about NYC, and the first to enroll women in an HIV-era cohort study.
• First to assess geographic distribution of asthma in children across an entire state.
• First to discover confirmed very high rates of HCV in IDU’s, presaging the epidemic consequences of HCV (liver failure and hepatocellular carcinoma).
• A member of the team demonstrating immunologic abnormalities associated with HTLV-II, such as spontaneous lymphocyte proliferation and lymphocyte subset changes.

Dr. Weiss is the immediate past Chair of the International Joint Policy Committee of the Societies of Epidemiology (see: www.ijpc-se.org). He has continuously served on the Executive Board of the NJPHA since 1993, through the terms of over a dozen NJPHA presidents, and the founding Chair of its Epidemiology Section. He is a past chair of the Epidemiology Section and past vice-chair of the Science Board of the American Public Health Association. He is a longstanding member of the Coordinating Committee of the Pediatric/Adult Asthma Coalition of NJ and co-chair of its Evaluation Workgroup, and the Community Liaison Physician of the NJMS/University Hospital Oncology Program to the CoC and the vice-chair of its Oncology Committee.  

As the founder and director of the Essex County Cancer Coalition and of its expanded successor, the Essex-Passaic Chronic Disease Coalition (a.k.a. the Essex-Passaic Wellness Coalition; http://web.njms.rutgers.edu/EPWC), he helps implement community-based education, outreach, screening and prevention of cancer and is a public policy advocate.   

His RBHS teaching has focused on evidence-based medicine approaches and critical analysis of medical literature, and the epidemiology and prevention of both chronic and infectious diseases.  He served in 2012-13 as the co-course director of the 2nd year NJMS “Disease Processes, Prevention & Therapeutics” course. He also teaches in the RBHS School of Public Health.  

Other professional affiliations include the NJ Allergy, Asthma & Immunology Society, the NY Allergy and Asthma Society, the American Society of Clinical Oncology, Alpha Omega Alpha (the medical honor society; he is the assistant secretary-treasurer of the Beta Chapter of NJ), the Society for Epidemiologic Research, the International Epidemiological Association, and one of the Founding Members of the Infectious Disease Society of NJ.  He is a past Fellow of the Infectious Diseases Society of America. He’s been in leadership roles for each of the four North American Congresses of Epidemiology.

SANOFI IS A GLOBAL HEALTHCARE LEADER FOCUSED ON PATIENTS’ NEEDS

engaged in the research, development, manufacturing and marketing of therapeutic solutions focused on patients’ needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme.

Type 1 diabetes (T1D), formerly known as juvenile diabetes, is a chronic, life-threatening disease that affects millions of people worldwide. In the United States, 30,000 new cases are estimated every year with half of those cases diagnosed in young children. Type 1 diabetes is an autoimmune disease in which the patient’s immune system goes awry and attacks and destroys the pancreatic beta cells. Beta cells are responsible for regulating blood sugar (glucose) levels by producing precise amounts of the essential hormone insulin.

The discovery of injectable insulin in the 1920s changed T1D from a uniformly fatal disease with a life expectancy of months to one that could be carefully managed for decades through multiple daily blood glucose measurements and insulin injections. However, insulin injections are not a cure and patients face a lifetime of difficult disease management and serious complications including kidney failure, blindness and nerve damage. Despite nearly a century passing since the discovery of insulin, insulin injection remains the only treatment available to patients.

Semma Therapeutics was founded to develop transformative therapies for patients who currently depend on insulin injections. Recent work in the laboratory of Professor Douglas Melton led to the discovery of a method to generate billions of functional, insulin-producing beta cells in the laboratory. These cells develop in islet-like clusters grown from stem cells. Initial preclinical work in animal models of diabetes has shown that transplantation of these cells are sufficient to control blood glucose levels. This breakthrough technology has been exclusively licensed to Semma Therapeutics for the development of a cell-based therapy for diabetes.

Ongoing research at Semma Therapeutics is focused on combining these proprietary cells with a state-of-the-art cell delivery and immune protection strategy that can protect these cells from the patient’s immune system and allow the beta cells to function as they do in non-diabetic individuals. Implantation of the beta cell-filled device has the potential to provide a true replacement for the missing beta cells in a diabetic patient and would not require patient immunosuppression. Semma Therapeutics is working to bring this new therapeutic option to the clinic and improve the lives of patients with diabetes.